Clinical Trials: Improving Care of Women with Breast Cancer Through Research

Similar documents
Adjuvant Systemic Therapy in Early Stage Breast Cancer

Systemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Evolving Practices in Breast Cancer Management

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.

4/13/2010. Silverman, Buchanan Breast, 2003

Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002

COME HOME Innovative Oncology Business Solutions, Inc.

Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer

Ideal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria

Breast Cancer Treatment

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD

Latest News in Breast Cancer Research

What is the Oncotype DX test?

Key Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Systemic Management of Breast Cancer

The worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials

Update from the 29th Annual San Antonio Breast Cancer Symposium

Chapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:

Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology

Beyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

Toxicities of Chemotherapy Regimens used in Early Breast Cancer

It is a malignancy originating from breast tissue

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst

Understanding Tumor Markers for Breast and Colorectal Cancers. A Patient s Guide. Recommendations of the American Society of Clinical Oncology

Breast Cancer. Dr. Andres Wiernik 2017

Dr. Som Mukherjee MD, MSc, FRCP(C) Juravinski Cancer Centre October 19, 2011

Nadia Harbeck Breast Center University of Cologne, Germany

Breast Cancer Scanning the Horizon

Breast Cancer Breast Managed Clinical Network

American Society of Clinical Oncology June , New Orleans

Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics

Invasive Breast Cancer

Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey


Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Clinical Management Guideline for Breast Cancer

European consortium study on the availability of anti-neoplastic medicines

HER2-positive Breast Cancer

Hormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute

Systemic Therapy Considerations in Inflammatory Breast Cancer

Metastatic Breast Cancer What is new? Subtypes and variation?

A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer

Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data. Chapter 5

BreastCancerAdvisor by DR. SILVANA MARTINO January 2014

BREAST CANCER AND BONE HEALTH

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM

Educator Navigation Guide

Breast Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology

Lessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1

Lessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh

Horizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887

Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer

Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

The Three Ages of Systemic Adjuvant Therapy for EBC

Breast Cancer Treatment, Outcomes and Recent Advances. Ogori N Kalu, MD, MS Director Breast Surgery-UH Asst. Prof of Surgery Rutgers NJ Med School

DEFINITION. Breast cancer is cancer that forms in the. more common in women.

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Cancer Care Ontario Practice Guidelines Initiative Sponsored By: Cancer Care Ontario & the Ministry of Health and Long-term Care

Breast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA

Media Release. Basel, 3 June 2012

A Guide for Women with Breast Cancer

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer

Breast Cancer. Controversies in the Therapy of Early Stage Breast Cancer. The Oncologist 2005;10:

The HERA Study Team. Presented by Ian E. Smith

Advances in Neoadjuvant and Adjuvant Therapy for Breast Cancer

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Breast Cancer & Personalized Medicine

A breast lump or thickening that feels different from the surrounding tissue

/ NCCN. ACS ( NCC ( NCCN NCCN ACS ACS-2345

Standard Breast Cancer Therapy

BreastCancerAdvisor by DR. SILVANA MARTINO AUGUST 2011

ESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer

See Important Reminder at the end of this policy for important regulatory and legal information.

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc

COLORECTAL CANCER 44

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

A vision for HER2 future

THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?

State of the Art in 2000 State of the Art today Gazing forward

Breast. Presentation Outline

Breast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Newly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center

Supplementary Online Content

Triple Negative Breast Cancer: Part 2 A Medical Update

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

ASCO and San Antonio Updates

Breast Cancer. Metastatic NCCN GUIDELINES FOR PATIENTS Available online at NCCN.org/patients. Please complete. our online survey at

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

Transcription:

Clinical Trials: Improving Care of Women with Breast Cancer Through Research Som Mukherjee MD, MSc, FRCP(C) Life After Breast Cancer October 17, 2013

Breast Cancer

Is research making a difference?

Waging the war against cancer

Questions to answer today What is a clinical trial? How has research in breast cancer helped us get to where we are today? What are the pros and cons of joining a clinical trial? Breast cancer trials at the Juravinski Cancer Centre: is there a study out there that can help me? What does the future hold for breast cancer research?

Why is cancer such a difficult disease to cure?

Inside the Breast Cancer Cell

How did we get here? A Brief History of Breast Cancer Research

Earliest research 1600 B.C. Ancient Egypt Several cases of ulcerous tumours of the breast It was written that there is no treatment

A Brief History In the 1700 s, it was commonly thought that breast cancer was caused by: too little sexual activity too much sexual activity trauma to the breast clothing that was too tight

History of Breast Cancer Breast cancer was not as common until 1800 s, when infectious diseases were better controlled, sanitation improved and lifespan started to increase dramatically At that time, surgery had a high mortality rate

Life Expectancy

Age and Risk of Breast Cancer Age 0-39 1 in 203 women Age 40 to 59 1 in 27 women Age 60 to 69 1 in 28 women Age 70 and older 1 in 15 women

Breast Cancer Research Surgery Dr. Halstead (1852 1922) published research on the radical mastectomy and this dramatically improved mortality rates in breast cancer Modified radical mastectomy Lumpectomy and radiation vs. mastectomy

Breast Cancer Research: Hormonal Therapy 1896 - Sir George Beaton, Scottish Surgeon discovered the link between breast cancer and hormones Published 3 cases of women with breast cancer which shrunk dramatically after removal of their ovaries, which was performed for other reasons

Breast Cancer Research - Chemotherapy 1960 s Dr. Fisher and Dr. Bonnadonna discovered that chemotherapy given after surgery improved the cure rate for breast cancer patients 1970-1990 anthracyclines (doxorubicin, adriamycin) 1987 paclitaxel found to be effective (Taxol) 2000 s Hamilton-led trials: MA-5, Dr. Mark Levine et al CEF vs. CMF MA-21, Dr. Mark Levine et al CEF, AC/T, dose dense EC/T

Back to the present: Clinical Trials at the JCC

What is a Clinical Trial? A clinical trial is a type of research that uses human volunteers (also called participants) and is intended to add to medical knowledge Clinical trials allow patients the possibility to receive a new type of treatment or test

Types of Research at the JCC

Clinical Trials at the JCC The Clinical Trials Department at JCC is one of the largest in Canada Oncologists recruit 800-1000 patients to over 70 different clinical trials at JCC every year Many breast cancer clinical trials currently open at JCC

Recent JCC Clinical Trials in Breast Cancer

1. Radiation Trials Dr. Tim Whelan Radiation trials looking at fewer number of treatments following surgery for breast cancer 16 treatments equivalent to 25 treatments for women with early stage breast cancer following lumpectomy this has impacted on treatment across the world Looking at trying to determine if 5 days of treatment suitable for certain patients

2. HERA Trial CANADA 71.5% NORDIC COUNTRIES EU EASTERN EUROPE: 11% JAPAN CENTRAL & SOUTH AMERICA 5.5% 12% ASIA PACIFIC SOUTH AFRICA AUSTRALIA NEW ZEALAND

Herceptin

HERA Trial Women who received chemotherapy after surgery were randomized to receive no Herceptin (trastuzumab) or 1 year of Herceptin or 2 years of Herceptin Results presented in 2006 showed that 1 year of Herceptin was better than no Herceptin (recurrence rate almost half at 2 years) Cure rates for HER2 +ve breast cancer have improved significantly (24% decrease) since the arrival of Herceptin

Insulin and Cancer

3. MA-32: Metformin in Breast Cancer New research suggests that insulin helps to increase the ability of cancer cells to grow, divide and spread Clinical trial of metformin in breast cancer has completed accrual Preliminary results presented at ASCO 2013 showed that metformin resulted in weight loss, improved glucose levels and lower insulin levels Awaiting results of data looking at breast cancer recurrence rates

4. LISA Trial Randomized controlled trial evaluating the usefulness of a telephone-based lifestyle intervention vs. written material Results presented at ASCO 2013 Showed that significant weight loss was seen after 6, 12 and 18 months of a lifestyle intervention

5. Hamilton led MA-21 trial Women with high risk breast cancer randomized to one of 3 treatment groups: AC/T every 3 weeks Dose dense EC/T CEF chemotherapy Results showed that AC/T given every 3 weeks was not as effective as the other 2 regimens

6. Oncotype Dx Trials Oncotype Dx is a new tool that helps oncologists determine if a patient might benefit from adjuvant chemotherapy (following surgery) McMaster University/JCC are leading this study through the Ontario Clinical Oncology Group to determine how often this test changes treatment plans in patients

Hope for the Future Knowledge gained from clinical trials has led the way and improved the treatment of breast cancer Generations of patients before us have helped us figure out how best to treat our patients Research gives us all hope

Working Together Worldwide Worldwide movement of research Conferences sharing research: CAMO, ASCO, ESMO

Are we making progress in breast cancer?

Better Prevention

Improved Diagnosis

Better Treatments Surgery Radiation

Better Treatments New breast cancer drugs approved by Health Canada over past 10 years: Herceptin (trastuzumab) and lapatinib (Tykerb) for HER2 +ve breast cancer T-DM1, pertuzumab Hormonal therapies aromatase inhibitors (letrozole (Femara), anastrazole (Arimidex), exemestane (Aromasin) Everolimus (Afinitor) Chemotherapy eribulin Bone agents denosumab, pamidronate

What about me? Why Should I Participate in Clinical Trials? Possibility that you could benefit yourself from new treatments Opportunity to help other patients in the future Increase global understanding of breast cancer

Active Breast Cancer Trials at the JCC www.jcc.hhsc.ca Click on Clinical Trials

Journey Story on the battle against cancer not over yet Final chapter has yet to be written Our understanding of cancer has increased dramatically over the past 50 years and continues to increase on a daily basis

My Vision for the Future

Clinical trials are the vital link between breakthroughs in the lab and new treatments that extend and improve patients lives

The Real Heroes of Research (you!)

Thank You!